| Mary Rimi, | |
|
1012 North Point Rd, Baltimore, MD 21224-3338 | |
| (443) 216-4800 | |
| Not Available |
| Full Name | Mary Rimi |
|---|---|
| Gender | Female |
| Speciality | Counselor - Mental Health |
| Location | 1012 North Point Rd, Baltimore, Maryland |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013308576 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mary Rimi, 1012 North Point Rd, Baltimore, MD 21224-3338 Ph: (443) 216-4800 | Mary Rimi, 1012 North Point Rd, Baltimore, MD 21224-3338 Ph: (443) 216-4800 |
News Archive
A group of researchers including a Concordia PhD student have developed a new method of bioprinting adult neuron cells. They're using a new laser-assisted technology that maintains high levels of cell viability and functionality.
Resistance to chemotherapy treatments can be the worst news a cancer patient ever receives. A pair of researchers at the University of Missouri-Columbia is working steadfastly to learn why some tumors eventually build a tolerance to the common chemotherapy drug cisplatin, in hopes of identifying the particular genes that can be manipulated to make treatment as effective as possible.
Even in an Asian nation where people generally have higher levels of physical activity on the job than is typical in North America or Europe, those who walk more or engage in regular sports activity tend to have lower levels of ischemic stroke and coronary heart disease
YM BioSciences Inc., today announced that the first US patient has been enrolled in its randomized, double-blind trial evaluating nimotuzumab in patients with brain metastases from NSCLC at the Florida Cancer Institute - New Hope. This trial initiation follows recent clearance from the US FDA announced on January 26, 2010 allowing the Company to enroll patients at US clinical sites for two of its international and ongoing randomized, double-blind Phase II trials of nimotuzumab.
A protein highly expressed in lung cancer cells drives resistance to targeted therapies, report researchers at the Medical University of South Carolina in the Journal of Thoracic and Cardiovascular Surgery.
› Verified 6 days ago
Mrs. Janet Louise Hughes, LCSW-C Counselor Medicare: Medicare Enrolled Practice Location: 1501 S. Clinton St, Mailstop Ct 05-13, Baltimore, MD 21224 Phone: 443-904-1468 | |
Nadine Castro, Counselor Medicare: Not Enrolled in Medicare Practice Location: 2225 N Charles St, Baltimore, MD 21218 Phone: 410-366-4360 Fax: 443-830-1521 | |
Jinaki Olatunji, Counselor Medicare: Not Enrolled in Medicare Practice Location: 2215 N Charles St, Baltimore, MD 21218 Phone: 443-573-8673 | |
Rachel Sheffel, Counselor Medicare: Not Enrolled in Medicare Practice Location: 3400 Chestnut Ave Fl 2, Baltimore, MD 21211 Phone: 703-371-8581 | |
Ms. Hannah Elise Rose, LCPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 711 W 40th Street, Suite 425, Baltimore, MD 21211 Phone: 443-845-1573 Fax: 443-787-0306 | |
Tasha Nate Allen, LCPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 1 E Chase St Ste 1128, Baltimore, MD 21202 Phone: 443-355-3992 | |
Nicholas A Etheridge, LCPC, NCC Counselor Medicare: Not Enrolled in Medicare Practice Location: 5500 Harford Rd Ste 201, Baltimore, MD 21214 Phone: 667-706-9091 |